California leads the world in biotech productivity and innovation, and Joseph Panetta, President & CEO of Biocom, has been at the center of the growth of the San Diego biotech ecosystem since 1989. In this podcast, we discuss the various international pricing proposals being discussed in Washington DC, and their potential negative impact on the California biopharma ecosystem.

Biocom is an association that advocates for 1200 companies, service sector firms, universities and research institutes working in the biotechnology sector. As President and CEO since 1999, Mr. Panetta leads programs in capital formation, public policy, workforce education, and member-to-member services. He is a co-founder of the Biocom Political Action Committee, the Biocom Institute for education and workforce development, and the California Biotechnology Foundation, a joint initiative to inform legislators and the media about the life science industry in the state, of which he is Chairman.

Research quoted:
https://vitaltransformation.com/2019/11/international-reference-pricing-under-h-r-3-would-devastate-the-emerging-biotechnology-sector-leading-to-56-fewer-new-medicines-coming-to-market-over-10-years/
https://healtheconomicsreview.biomedcentral.com/articles/10.1186/s13561-014-0023-5
https://www.hbs.edu/faculty/Publication%20Files/09-118.pdf

See omnystudio.com/listener for privacy information.